Glycoheal G 1002 Tablet SR is a sustained-release oral hypoglycemic agent containing a combination of Glimepiride 2mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, enhances pancreatic insulin secretion, thereby improving glycemic control, while Metformin, a biguanide, primarily reduces hepatic glucose production and increases peripheral insulin sensitivity. This combination offers a complementary mechanism of action, making it effective in patients inadequately controlled on diet, exercise, or monotherapy. The sustained-release formulation ensures a gradual release of active ingredients, promoting better glycemic stability and reducing gastrointestinal side effects commonly associated with Metformin. Glycoheal G 1002 is prescribed as part of a comprehensive diabetes management plan, including diet and lifestyle modifications. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, or known hypersensitivity to its components. Caution is advised in patients with cardiovascular disease or conditions predisposing to hypoglycemia. Regular monitoring of blood glucose levels, renal function, and lactic acid levels is recommended during therapy. Adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. Patient adherence and periodic clinical evaluation are essential to optimize therapeutic outcomes.